Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
NCT ID: NCT05616598
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
200 participants
INTERVENTIONAL
2022-03-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
NCT03510637
Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse
NCT04662138
ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
NCT04387539
Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children
NCT05091008
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
NCT03163849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pateint group
Men with HCV
Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
Control group
Men without HCV
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Essam Mohamed El-sayed Akl
Assistant Professor of Dermatology and Andrology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Benha University
Al Qalyūbīyah, Benha, Egypt
Benha Faculty of Medecine
Banhā, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC 39-10-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.